Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 285

1.

Discontinuing combination antiretroviral therapy during the first trimester of pregnancy: insights from plasma human immunodeficiency virus-1 RNA viral load and CD4 cell count.

Bucceri AM, Somigliana E, Matrone R, Uberti-Foppa C, Viganò P, Vignali M.

Am J Obstet Gynecol. 2003 Aug;189(2):545-51.

PMID:
14520232
2.

HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy.

Tamburrini E, Ravizza M, Floridia M, Tibaldi C, Alberico S, Anzidei G, Maccabruni A, Meloni A, Antoni AD, Mori F, Dalzero S, Conservan V, Pinnetti C, Ferrazzi E; Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy.

Antivir Ther. 2008;13(4):519-27.

PMID:
18672530
3.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)].

Panel de expertos de GESIDA; Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2007 Jan;25(1):32-53. Spanish.

PMID:
17261244
4.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2009 Oct;27(8):491.

PMID:
19246124
5.

Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women.

McGowan JP, Crane M, Wiznia AA, Blum S.

Obstet Gynecol. 1999 Nov;94(5 Pt 1):641-6.

PMID:
10546703
6.

Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.

Fernández Guerrero ML, Rivas P, Molina M, Garcia R, De Górgolas M.

Clin Infect Dis. 2005 Aug 1;41(3):390-4. Epub 2005 Jun 22.

PMID:
16007538
7.

Is the interruption of antiretroviral treatment during pregnancy an additional major risk factor for mother-to-child transmission of HIV type 1?

Galli L, Puliti D, Chiappini E, Gabiano C, Ferraris G, Mignone F, Viganò A, Giaquinto C, Genovese O, Anzidei G, Badolato R, Buffolano W, Maccabruni A, Salvini F, Cellini M, Ruggeri M, Manzionna M, Bernardi S, Tovo P, de Martino M; Italian Register for HIV Infection in Children.

Clin Infect Dis. 2009 May 1;48(9):1310-7. doi: 10.1086/597774.

PMID:
19309307
8.

Short-term anti-HIV activity of the combination of didanosine and hydroxyurea.

Clotet B, Ruiz L, Cabrera C, Ibáñez A, Cañadas MP, Sirera G, Romeu J, Vila J.

Antivir Ther. 1996 Aug;1(3):189-93.

PMID:
11322253
9.

Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels.

Ahdieh Grant L, Silverberg MJ, Palacio H, Minkoff H, Anastos K, Young MA, Nowicki M, Kovacs A, Cohen M, Muñoz A.

AIDS. 2001 Nov 9;15(16):2101-8.

PMID:
11684929
10.

Antiretroviral treatment during pregnancy.

Keiser O, Gayet-Ageron A, Rudin C, Brinkhof MW, Gremlich E, Wunder D, Drack G, Hirschel B, de Tejada BM; Swiss HIV Cohort Study (SHCS); Swiss Mother & Child HIV Cohort Study (MoCHiV).

AIDS. 2008 Nov 12;22(17):2323-30. doi: 10.1097/QAD.0b013e3283189bf1.

PMID:
18981771
11.

Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.

Lyons FE, Coughlan S, Byrne CM, Hopkins SM, Hall WW, Mulcahy FM.

AIDS. 2005 Jan 3;19(1):63-7. Erratum in: AIDS. 2007 Jul 31;21(12):1671.

PMID:
15627034
12.

The influence of pregnancy on human immunodeficiency virus type 1 infection: antepartum and postpartum changes in human immunodeficiency virus type 1 viral load.

Burns DN, Landesman S, Minkoff H, Wright DJ, Waters D, Mitchell RM, Rubinstein A, Willoughby A, Goedert JJ.

Am J Obstet Gynecol. 1998 Feb;178(2):355-9.

PMID:
9500499
13.
14.

The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.

Anastos K, Barrón Y, Cohen MH, Greenblatt RM, Minkoff H, Levine A, Young M, Gange SJ.

Ann Intern Med. 2004 Feb 17;140(4):256-64.

PMID:
14970148
15.

Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.

Olsen CH, Gatell J, Ledergerber B, Katlama C, Friis-Møller N, Weber J, Horban A, Staszewski S, Lundgren JD, Phillips AN; EuroSIDA Study Group.

AIDS. 2005 Feb 18;19(3):319-30.

PMID:
15718843
16.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group.

Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.

PMID:
15909251
17.

The relationship of pregnancy to human immunodeficiency virus disease progression.

Minkoff H, Hershow R, Watts DH, Frederick M, Cheng I, Tuomala R, Pitt J, Zorrilla CD, Hammill H, Adeniyi-Jones SK, Thompson B.

Am J Obstet Gynecol. 2003 Aug;189(2):552-9.

PMID:
14520233
18.

Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.

Ruiz L, Romeu J, Ibáñez A, Cabrera C, Puig T, Morales MA, Sirera G, Clotet B.

Antivir Ther. 1996 Dec;1(4):220-4.

PMID:
11324824
19.

Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points.

Wu H, Kuritzkes DR, McClernon DR, Kessler H, Connick E, Landay A, Spear G, Heath-Chiozzi M, Rousseau F, Fox L, Spritzler J, Leonard JM, Lederman MM.

J Infect Dis. 1999 Apr;179(4):799-807.

PMID:
10068574
20.

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.

AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77.

PMID:
18670217

Supplemental Content

Support Center